Axxam has established a discovery research program to identify and develop pre-clinical candidates for a variety of biological important targets, but primarily targeting GPCRs and ion channels, in the therapeutic areas of Pain, Metabolic Disorders and Autoimmune Diseases.

Axxam applies its in-depth knowledge and expertise for GPCRs, ion channels and advanced screening technologies to identify small molecule modulators using Axxam's^™ small molecule screening collection AXX^DIV which sets the ground to start the Hits to Leads process.

We continue to actively seek new partners for current and future projects.
Please, contact us to enquire about prospects for partnering with Axxam.